GlaxoSmithKline plc (LON:GSK) had its price target boosted by Jefferies Group from GBX 1,900 ($23.51) to GBX 1,950 ($24.13) in a research note released on Thursday morning. Jefferies Group currently has a buy rating on the stock.

A number of other analysts have also commented on the stock. Societe Generale lowered shares of GlaxoSmithKline plc to a sell rating and boosted their price objective for the stock from GBX 1,300 ($16.09) to GBX 1,320 ($16.34) in a research report on Thursday, September 8th. JPMorgan Chase & Co. reissued a neutral rating and issued a GBX 1,900 ($23.51) price objective on shares of GlaxoSmithKline plc in a research report on Tuesday, August 23rd. BNP Paribas reissued an underperform rating and issued a GBX 1,520 ($18.81) price objective on shares of GlaxoSmithKline plc in a research report on Friday, September 30th. Deutsche Bank AG reissued a hold rating and issued a GBX 1,870 ($23.14) price objective on shares of GlaxoSmithKline plc in a research report on Wednesday. Finally, Liberum Capital reissued a buy rating and issued a GBX 1,900 ($23.51) price objective on shares of GlaxoSmithKline plc in a research report on Tuesday, September 20th. Three investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eight have issued a buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of GBX 1,687.13 ($20.88).

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

GlaxoSmithKline plc (LON:GSK) traded down 0.29% during mid-day trading on Thursday, reaching GBX 1695.00. 4,656,506 shares of the company’s stock traded hands. GlaxoSmithKline plc has a 1-year low of GBX 1,277.25 and a 1-year high of GBX 1,745.56. The firm has a 50 day moving average of GBX 1,649.81 and a 200 day moving average of GBX 1,561.10. The firm’s market cap is GBX 82.39 billion.

The business also recently announced a dividend, which was paid on Thursday, October 13th. Shareholders of record on Thursday, August 11th were issued a dividend of GBX 19 ($0.24) per share. This represents a yield of 1.12%. The ex-dividend date of this dividend was Thursday, August 11th.

In other GlaxoSmithKline plc news, insider Slaoui,Moncef acquired 28 shares of the business’s stock in a transaction dated Friday, August 12th. The stock was bought at an average price of GBX 2,208 ($27.33) per share, with a total value of £618.24 ($765.15). Also, insider Witty,Sir Andrew P sold 10,000 shares of the business’s stock in a transaction dated Wednesday, July 27th. The stock was sold at an average price of GBX 1,693 ($20.95), for a total value of £169,300 ($209,529.70).

About GlaxoSmithKline plc

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Receive News & Stock Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related stocks with our FREE daily email newsletter.